Showing results (241-250 of 3,351) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|February 24, 2009
Stents as sole therapy for oesophageal cancer: a prospective analysis of outcomes after placementRussell E White, Robert K Parker, John W Fitzwater, et al.
The Lancet. Oncology|February 24, 2009
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyPierre Fenaux, Ghulam J Mufti, Eva Hellstrom-Lindberg, et al.
The Lancet. Oncology|February 10, 2009
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II studyEzra E W Cohen, Darren W Davis, Theodore G Karrison, et al.
The Lancet. Oncology|April 4, 2009
Adjuvant radiation therapy for high-risk nodal metastases from cutaneous melanomaB Ashleigh Guadagnolo, Gunar K Zagars
The Lancet. Oncology|July 17, 2009
Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trialRoger Stupp, Michael Mayer, Roger Kann, et al.
The Lancet. Oncology|August 14, 2009
Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trialsDavid P Dearnaley, Malcolm D Mason, Mahesh K B Parmar, et al.
The Lancet. Oncology|February 16, 2010
The metabolic syndrome in cancer survivorsEsther C de Haas, Sjoukje F Oosting, Joop D Lefrandt, et al.
The Lancet. Oncology|February 16, 2010
Teleoncology: current and future applications for improving cancer care globallyRibhi Hazin, Ibrahim Qaddoumi
The Lancet. Oncology|September 18, 2016
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre studySusan O'Brien, Jeffrey A Jones, Steven E Coutre, et al.
The Lancet. Oncology|May 28, 2017
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trialRajen Mody, Arlene Naranjo, Collin Van Ryn, et al.
Pageof 336